Ethyl 2-ethoxy-1-[[(2'-cyanobiphenyl-4-yl)methyl]benzimidazole]-7-carboxylate, 95.0%, 1g

7-Iodo-1H-indazole, 95.0%, 5g

3-(2,2,2-TRIFLUOROETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE, 95.0%, 1g

2,2,3,3,3-Pentafluoropropylamine>97.0%(GC)5g

5-(CHLOROMETHYL)-1,3-DIMETHYL-1H-PYRAZOLE HCL, 95.0%, 250mg

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)butanoic acid, 95%, 250mg

Ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate, 95.0%, 25g

rel-tert-Butyl (3aR,8aS)-octahydropyrrolo[3,4-c]azepine-5(1H)-carboxylate oxalate, 95%, 1g

(3-(N-(P-TOLYL)SULFAMOYL)PHENYL)BORONIC ACID, 95%, 1g

2-Ethylhexyl Methacrylate (stabilized with MEHQ)>99.0%(GC)25mL

Phase contrast Abbe condenser with slide for Plan PLPHi 20/S100 phase contrast infinity corrected objectives, slide with 20 and 100x phases, telescope and green filter

tert-Butyl (3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate, 95%+, 25g

2,2-Dimethylsuccinic acid, 95.0%, 10g